Clinical Trial Update: NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions [Phase 4]

View source ↗

Summary

The Phase 4 NEWTON trial evaluating aflibercept intravitreal injection for macular edema due to central retinal vein occlusion has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Edema Due to Central Retinal Vein Occlusion

Drugs mentioned

• Aflibercept intravitreal injection (EYLEA) (aflibercept)

Snippet

Sponsor: Northern California Retina Vitreous Associates | Conditions: Macular Edema With Central Retinal Vein Occlusions | Phase 4 | Status: COMPLETED